Parkinson's disease: A role for the immune system

Current Molecular Pharmacology

Volumn 5, Issue 3, 2012, Pages 340-349

  German, Dwight C ^a   Eagar, Todd ^a   Sonsalla, Patricia K ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Glia; Inflammation; MPTP; Neurodegeneration; Peptoids; T cells

Indexed keywords

AMYLOID BETA PROTEIN[1-42] ANTIBODY; ANTIBODY; BIOLOGICAL MARKER; DOPAMINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; LEWY BODY; MICROGLIA; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

EID: 84874919774     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205030003     Document Type: Review

References (75)

1. Gelb, D.J.; Oliver, E.; Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol., 1999, 56, 33-39.
2. Grimberger, Y.A.; Langston, J.W.; Roos, R.A.; Bloem, B.R. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev. Neurother., 2009, 9(2), 279-290.
3. Ansari, K.A.; Johnson, A. Olfactory function in patients with Parkinson's disease. J. Chronic Dis., 1975, 28, 493-497.
4. Muller, A.; Reichmann, H.; Livermore, A.; Hummel, T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J. Neural. Transm., 2002, 109, 805-811.
5. Pfeiffer, R.R.; Bodis-Wollner, I. Parkinson's disease and nonmotor dysfunction. Humana Press, Totowa, NJ, 2005.
6. Kupsky, W.J.; Grimes, M.M.; Sweeting, J.; Bertsch, R.; Cote, L.J. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology, 1987, 37, 1253-1255.
7. Halliday, G.M.; Blumbergs, P.C.; Cotton, R.G.; Blessing, W.W.; Geffen, L.B. Loss of brainstem serotonin-and substance Pcontaining neurons in Parkinson's disease. Brain Res., 1990, 510, 104-107.
8. Remy, P.; Doder, M.; Lees, A.; Turjanski, N.; Brooks, D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128, 1314-1322.
9. Langston, J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol., 2006, 59(4), 591-596.
10. Hassler, R. Zur pathologischen anatomie des senilen und des parkinsonistichen tremor. J. Psychol. Neurol., 1939, 49, 13-55.
11. German, D.C.; Manaye, K.; Smith, W.K.; Woodward, D.J.; Saper, C.B. Midbrain dopaminergic cell loss in Parkinson's Disease: computer visualization. Ann. Neurol., 1989, 26, 507-514.
12. Braak, H.; Ghebremedhin E.; Rüb U.; Bratzke H.; Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res., 2004, 318, 121-134.
13. German, D.C.; Manaye, K.F.; White, C.L.; Woodward, D.J.; McIntire, D.D.; Smith, W.K.; Kalaria, R.N.; Mann, D.M.A. Disease specific patterns of locus coeruleus cell loss. Ann. Neurol., 1992, 32, 667-676.
14. + T cells mediate cytotoxicity in neurodegenerative diseases. J. Clin. Invest., 2009, 119, 13-15.
15. Appel, S.H.; Beers, D.R.; Henkel, J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol., 2009, 31, 7-17.
16. Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol., 2009, 8, 382-397.
17. Ransohoff, R.M.; Perry, V.H. Microglial physiology: unique stimuli, specialized responses. Ann. Rev. Immunol., 2009, 27, 119-145.
18. Hald, A.; Lotharius, J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol., 2005, 193, 279-290.
19. Benoit, M.; Desnues B.; Mege J.L. Macrophage polarization in bacterial infections. J. Immunol. 2008, 181, 3733-3739.
20. McGeer, P.L.; Itagaki, S.; McGeer, E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol., 1988, 76, 550-555.
21. Hunot, S.; Dugas, N.; Faucheux, B.; Hartmann, A.; Tardieu, M.; Debré, P.; Agid, Y.; Dugas, B.; Hirsch, E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci., 1999, 19, 3440-3447.
22. Graham, D.G. On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med., 1979, 103, 359-362.
23. Mann, D.M.A.; Yates, P.O. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev., 1983, 21, 193-203.
24. Ellis, R.J. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol., 2001, 11, 114-119.
25. Liang, C-L.; Nelson, O.; Yazdani, U.; Pasbakhsh, P.; German, D.C. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J. Comp. Neurol., 2004, 473, 97-106.
26. Langston, J.W.; Forno, L.S.; Tetrud, J.; Reeves, A.G.; Kaplan, J.A.; Karluk, D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 1999, 46, 598-605.
27. Brochard, V.; Combadière B.; Prigent A.; Laouar Y.; Perrin A.; Beray-Berthat V.; Bonduelle O.; Alvarez-Fischer D.; Callebert J.; Launay J.M.; Duyckaerts C.; Flavell R.A.; Hirsch E.C.; Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest., 2009, 119, 182-192.
28. Szabo, S.J.; Sullivan, B.M.; Peng, S.L.; Glimcher, L.H. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol., 2003, 21, 713-758.
29. Ouyang, W.; Kolls, J.K.; Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity, 2008, 28(4), 454-467.
30. Sakaguchi, S.; Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T. Regulatory T cells: how do they suppress immune responses? Int. Immunol., 2009, 21(10), 1105-1111.
31. Wong, P.; Pamer, E.G. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol., 2003, 21, 29-70.
32. Wang, Y.M.; Alexander, S.I. CD8 regulatory T cells: What's old is now new. Immunol. Cell Biol., 2009, 87, 192-193.
33. Chen, S.; Le, W.D.; Xie, W.J.; Alexianu, M.E.; Engelhardt, J.I.; Siklós, L.; Appel, S.H. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch. Neurol., 1998, 55(8), 1075-1080.
34. He, Y.; Le, W.D.; Appel, S.H. Role of Fc-gamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp. Neurol., 2002, 176(2), 322-327.
35. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219(4587), 979-980.
36. 28k-containing cells. Ann. NY Acad. Sci., 1992, 648, 42-62.
37. German, D.C.; Nelson, E.L.; Liang, C.L.; Speciale, S.G.; Sinton, C.M.; Sonsalla, P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration, 1996, 5, 299-312.
38. Nicklas, W.J.; Youngster, S.K.; Kindt, M.V.; Heikkila, R.E. MPTP, MPP+ and mitochondrial function. Life Sci., 1987, 40, 721-729.
39. Lotharius, J.; Dugan, L.L.; O'Malley, K.L. Distinct mechanisms underlie neurotoxin mediated cell death in cultured dopaminergic neurons. J. Neurosci., 1999, 19, 1284-1293.
40. Greenamyre, J.T. Glutamatergic influences on the basal ganglia. Clin. Neuropharmacol., 2001, 24, 65-70.
41. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
42. Farrer, M. Comparison of kindreds with parkinsonism and asynuclein genomic multiplications. Ann. Neurol., 2004, 55, 174-179.
43. Liberatore, G.T.; Jackson-Lewis, V.; Vukosavic, S.; Mandir, A.S.; Vila, M.; McAuliffe, W.G.; Dawson, V.L.; Dawson, T.M.; Przedborski, S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 1999, 5, 1403-1409.
44. Wu, D.C.; Teismann, P.; Tieu, K.; Vila, M.; Jackson-Lewis, V.; Ischiropoulos, H.; Przedborski, S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 145-150.
45. Le, W.; Rowe, D.; Xie, W.; Ortiz, I.; He, Y.; Appel, S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci., 2001, 21, 8447-8455.
46. Cookson, M.R. alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009, 4, 9.
47. Lee, H.J.; Patel, S.; Lee, S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci., 2005, 25, 6016-6020.
48. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; Zhang, J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19, 533-542.
49. Gao, H.M.; Kotzbauer, P.T.; Uryu, K.; Leight, S.; Trojanowski, J.Q.; Lee, V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci., 2008, 28, 7687-7698.
50. Benner, E.J.; Banerjee R.; Reynolds A.D.; Sherman S., Pisarev V.M.; Tsiperson V.; Nemachek C.; Ciborowski P.; Przedborski S.; Mosley R.L.; Gendelman H.E. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One, 2008, 3, e1376.
51. Verreck, F.A.; de Boer, T.; Langenberg, D.M.; Hoeve, M.A.; Kramer, M.; Vaisberg, E.; Kastelein, R.; Kolk, A.; de Waal-Malefyt, R.; Ottenhoff, T.H. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc. Natl. Acad. Sci. USA, 2004, 101, 4560-4565.
52. Mount, M.P. Involvement of interferon-gamma in microglial mediated loss of dopaminergic neurons. J. Neurosci., 2007, 27, 3328-3337.
53. Kebir H.; Kreymborg, K.; Ifergan, I.; Dodelet-Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; Arbour, N.; Becher, B.; Prat, A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med., 2007, 13, 1173-1175.
54. Giuliani, F.; Goodyer, C.G.; Antel, J.P.; Yong, V.W. Vulnerability of human neurons to T cell mediated cytotoxicity. J. Immunol., 2003, 171, 368-379.
55. Meredith, G.E.; Sonsalla, P.K.; Chesselet, M-F. Animal models of Parkinson's disease progression. Acta Neuropathologica., 2008, 115, 385-398.
56. Kokovay, E.; Cunningham, L.A.; Kokovay, E.; Cunningham, L.A. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis., 2005, 19, 471-478.
57. Luchtman, D.W.; Shao, D.; Song, C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav., 2009, 98, 130-138.
58. Schintu, N.; Frau, L.; Ibba, M.; Garau, A.; Carboni, E.; Carta, A.R. Progressive dopaminergic degeneration in the chronic MPTP mouse model of Parkinson's disease. Neurotox. Res., 2009, 16, 127-139.
59. Sherer, T.B.; Betarbet, R.; Kim, J.H.; Greenamyre, J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett., 2003, 341, 87-90.
60. Sherer, T.B.; Betarbet, R.; Testa, C.M.; Seo, B.B.; Richardson, J.R.; Kim, J.H.; Miller, G.W.; Yagi, T.; Matsuno-Yagi, A.; Greenamyre, J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci., 2003, 23, 10756-10764.
61. +). Exp. Neurol., 2006, 200, 172-183.
62. Zeevalk, G.D.; Manzino, L.; Sonsalla, P.K.; Bernard, L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol., 2007, 203, 512-520.
63. Koprich, J.B.; Johnston, T.H.; Huot, P.; Fox, S.H.; Brotchie, J.M. New insights into the organization of the basal ganglia. Curr. Neurol. Neurosci. Rep., 2009, 9, 298-304.
64. Koprich, J.B.; Reske-Nielsen, C.; Mithal, P.; Isacson, O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation, 2008, 5, 8.
65. Sonsalla, P.K.; Wong, L-Y.; Harris, S.L.; German, D.C. Caffeine protects dopamine neurons in a progressive model of Parkinson's disease. Neurosci. Abstract, 2009, 430,25.
66. Sonsalla, P. K; Harris, S.; Wong, L-Y.; Richardson, J.R.; German, D.C. Protection of dopamine neurons in a progressive rat model of PD by captopril, an angiotensin converting enzyme inhibitor. Neurosci. Abstract, 2010, 858,1.
67. Du, Y.; Dodel, R.; Hampel, H.; Buerger, K.; Lin, S.; Eastwood, B.; Bales, K.; Gao, F.; Moeller, H.J.; Oertel, W.; Farlow, M.; Paul, S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology, 2001, 57, 801-805.
68. Papachroni, K.K.; Ninkina, N.; Papapanagiotou, A.; Hadjigeorgiou, G.M.; Xiromerisiou, G.; Papadimitriou, A.; Kalofoutis, A.; Buchman, V.L. Auto-antibodies to alpha-synuclein in inherited Parkinson's disease. J. Neurochem., 2007, 101, 749-756.
69. Gruden, M.A.; Davidova, T.B.; Malisauskas, M.; Sewell, R.D.; Voskresenskaya, N.I.; Wilhelm, K.; Elistratova, E.I.; Sherstnev, V.V.; Morozova-Roche, L.A. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: auto-antibodies to A (25-35) oligomers, S100b and neurotransmitters. J. Neuroimmunol., 2007, 186, 181-192.
70. Benkler, M.; Agmon-Levin N.; Hassin-Baer S.; Cohen O.S.; Ortega-Hernandez O.D.; Levy A; Moscavitch S.D.; Szyper-Kravitz M.; Damianovich M.; Blank M.; Chapman J.; Shoenfeld Y. Immunology, autoimmunity, and auto-antibodies in Parkinson's Disease. Clin. Rev. Allergy Immunol., 2012, 42(2), 164-171.
71. Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer's disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol., 2002, 37, 943-948.
72. Reddy, M.M.; Kodadek, T. Protein "fingerprinting" in complex mixtures with peptoid microarrays. Proc. Natal. Acad. Sci. USA, 2005, 102, 12672-12677.
73. Reddy, M.M.; Wilson, R.; Wilson, J.; Connell, S.; Gocke, A.; Hynan, L.; German, D.; Kodadek T. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell, 2011, 144, 132-142.
74. Reynolds, A.D.; Banerjee, R.; Liu, J.; Gendelman, H.E.; Mosley, R.L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol., 2007, 82, 1083-1094.
75. + T cell subsets. J. Immunol., 2009, 182, 4137-4149.